65,437 trials
Carcinoma, Non-Small-Cell Lung
Primary: Occurrence of Dose Limiting Toxicities (DLT) — 3; 2; 4; 3 Participants
Schizophrenia
Primary: Change in Cognition — 0.7 Change in BACS Composite Score
Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer
Primary: Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS — 4.79; 3.09 percentage of CD44+/ CD24+/ ESA+ cells
Healthy
Primary: Plasma Half Life of Labeled Carotenoid — 6.2; 2.3 days
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Fructosamine From Start of Ramadan to End of Ramadan — -13.2; -14.9 umol/L
Cancer of the Breast
Primary: Number of Patients Requiring 2nd Surgery for Close or Positive Margins — 22 participants
Diabetes Mellitus
Primary: Provider Abilities Scale - Subscale From the Midwest (MW) Clinicians' Network — 6.89; 6.41 units on a scale — p=0.26
Restless Legs Syndrome
Primary: Cmax,ss — 0.633; 1.13; NA; 0.396 ng/mL
Peripheral Arterial Disease (PAD)
Primary: Primary Patency — 82.2; 52.4 Percentage of participants — p=<0.001
Pain
Primary: Change in Pain Score on FLACC Scale From Device Deployment to Venipuncture — 1.71; 2.82; 0.23 units on a scale — p=0.0001
Body Dysmorphic Disorder
Primary: Yale Brown Obsessive Compulsive Scale (Modified for BDD) (BDD -YBOCS) (Phillips et al., 1997) — 23.47; 32.87; 21.37; 33.30 units on a scale — p=<.001
Helicobacter Pylori Infection
Primary: Number of Participants With Complete Eradication of Helicobacter Pylori — 102; 100; 101 participants
Duchenne Muscular Dystrophy
Primary: Safety and Tolerability — 14 participants
Diabetes Mellitus, Type 2
Primary: Proportion of Initiators for United Healthcare Patients — 2.8; 0.5; 0.2; 69.9 Percentage of participants
Asthma
Primary: Change From Baseline in Percent Predicted Morning (AM) Forced Expiratory Volume in 1 Second (FEV1) - MF MDI vs. Placebo — 4.52; 6.95; 6.00; 0.66 Percentage of Predicted…